Compare LZB & TRVI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | LZB | TRVI |
|---|---|---|
| Founded | 1927 | 2011 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Home Furnishings | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.3B | 1.4B |
| IPO Year | 1994 | 2019 |
| Metric | LZB | TRVI |
|---|---|---|
| Price | $35.97 | $15.45 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 11 |
| Target Price | ★ $42.50 | $21.55 |
| AVG Volume (30 Days) | 328.7K | ★ 1.5M |
| Earning Date | 02-17-2026 | 05-07-2026 |
| Dividend Yield | ★ 2.70% | N/A |
| EPS Growth | N/A | ★ 31.91 |
| EPS | ★ 1.65 | N/A |
| Revenue | ★ $2,349,433,000.00 | N/A |
| Revenue This Year | $1.89 | N/A |
| Revenue Next Year | $2.09 | N/A |
| P/E Ratio | $21.75 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $29.03 | $5.38 |
| 52 Week High | $44.49 | $15.76 |
| Indicator | LZB | TRVI |
|---|---|---|
| Relative Strength Index (RSI) | 66.98 | 78.31 |
| Support Level | $35.32 | $10.07 |
| Resistance Level | $39.71 | N/A |
| Average True Range (ATR) | 0.83 | 0.95 |
| MACD | 0.52 | 0.30 |
| Stochastic Oscillator | 91.47 | 86.20 |
La-Z-Boy Inc is a U.S.-based company that manufactures, distributes, and retails upholstery furniture products. It is a producer of reclining chairs and distributors of residential furniture in the U.S. The company chiefly operates in the United States but also has secondary operations in Canada and other countries. The company's reportable segments include the Wholesale segment, which manufactures and imports upholstered furniture; Retail, which sells upholstered and case goods furniture to the end consumer and corporate and others. The majority of the company's revenue is derived from its Wholesale segment.
Trevi Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of the investigational therapy Haduvio (oral nalbuphine ER) for the treatment of chronic cough in adults with idiopathic pulmonary fibrosis, or IPF, non-IPF interstitial lung disease, or non-IPF ILD, and refractory chronic cough, or RCC. Haduvio is an oral extended-release formulation of nalbuphine. The Company operates and manages its business as one reportable segment. Such a segment is the business of developing and commercializing the investigational therapy Haduvio.